Table 2 Characteristics of three patients with Neoehrlichia mikurensis detected in a plasma sample
From: Neoehrlichia mikurensis in Danish immunocompromised patients: a retrospective cohort study
Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
Sex/age | F/57 | M/72 | F/66 |
Blood sample positive for Neoehrlichia mikurensis DNA | October, 2016 | April, 2019 | November, 2019 |
Diagnosis above Blood sample positive for Neoehrlichia mikurensis DNA | Idiopathic thrombocytopenia | B-cell prolymphocytic leukemia | Chronic lymphocytic leukemia |
Immunosuppressive therapy at time of blood sampling | None1 | Rituximab + Venetoclax initiated same day as blood sampling | Rituximab + bendamustine initiated same day as blood sampling |
Time since the last dose of immunosuppressive therapy | None | Approx. 2.5 years | None |
Symptoms | |||
Fever | No | Yes | Yes |
Night sweats | No | Yes | Yes |
Fatigue | No | Yes | Yes |
Weight loss | No | Yes | Yes |
Thromboembolic complications | No | No | No |
Other symptoms | Easily bruised skin | Cough | Shortness of breath during activity, tinnitus |
Hemoglobin, reference 8.3–10.5 mmol/L (male), 7.3–9.5 mmol/L (female) | 9.7 mmol/L | 6.0 mmol/L | 5.4 mmol/L |
Platelets, reference 145–390 × 109/L | 26 × 109/L | 144 × 109/L | 154 × 109/L |
C-reactive protein, reference < 10 mg/L | N/A | 70 mg/L | 12 mg/L |
Splenomegaly (CT) | N/A | Yes | Yes |
Follow-up, May 2022 | |||
Status of immunosuppressive therapy | Approx. 10 months since last dose | Approx. 1.5 years since last dose | Approx. 2 years since last dose |
Follow-up real-time PCR for Neoehrlichia mikurensis DNA | Negative | Negative | Negative |
Antibiotics registered from blood sample to follow-up sample | None | Amoxicillin/clavulanic acid Ciprofloxacin Pivmecillinam Trimethoprim Nitrofurantoin Piperazilin/ tazobactam Azithromycin | Piperazilin/ tazobactam Sulfamethoxazole-trimethoprim |